Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors


Por: del Rey, J, Prat, E, Ponsa, I, Lloreta, J, Gelabert, A, Algaba, F, Camps, J, Miro, R

Publicada: 11 jun 2010
Resumen:
Background: Aneuploidy, centrosome abnormalities and gene amplification are hallmarks of chromosome instability (CIN) in cancer. Yet there are no studies of the in vivo behavior of these phenomena within the same bladder tumor. Methods: Twenty-one paraffin-embedded bladder tumors were analyzed by conventional comparative genome hybridization and fluorescence in situ hybridization (FISH) with a cyclin D1 gene (CCND1)/centromere 11 dual-color probe. Immunofluorescent staining of alpha, beta and gamma tubulin was also performed. Results: Based on the CIN index, defined as the percentage of cells not displaying the modal number for chromosome 11, tumors were classified as CIN-negative and CIN-positive. Fourteen out of 21 tumors were considered CIN-positive. All T1G3 tumors were included in the CIN-positive group whereas the majority of Ta samples were classified as CIN-negative tumors. Centrosome clustering was observed in six out of 12 CIN-positive tumors analyzed. CCND1 amplification in homogeneously staining regions was present in six out of 14 CIN-positive tumors; three of them also showed amplification of this gene in double minutes. Conclusions: Complex in vivo behavior of CCND1 amplicon in bladder tumor cells has been demonstrated by accurate FISH analysis on paraffin-embedded tumors. Positive correlation between high heterogeneity, centrosome abnormalities and CCND1 amplification was found in T1G3 bladder carcinomas. This is the first study to provide insights into the coexistence of CCND1 amplification in homogeneously staining regions and double minutes in primary bladder tumors. It is noteworthy that those patients whose tumors showed double minutes had a significantly shorter overall survival rate (p < 0.001).

Filiaciones:
del Rey, J:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Dept Biol Cellular Fisiol & Immunol, Bellaterra 08193, Spain

Prat, E:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Dept Biol Cellular Fisiol & Immunol, Bellaterra 08193, Spain

Ponsa, I:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Dept Biol Cellular Fisiol & Immunol, Bellaterra 08193, Spain

Lloreta, J:
 Univ Pompeu Fabra, IMAS, Hosp Mar, Dept Patol, Barcelona 08003, Spain

Gelabert, A:
 IMAS UAB, Hosp Mar, Dept Urol, Barcelona 08003, Spain

Algaba, F:
 Univ Autonoma Barcelona, Dept Patol, Barcelona 08025, Spain

Camps, J:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Dept Biol Cellular Fisiol & Immunol, Bellaterra 08193, Spain

 NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

Miro, R:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Dept Biol Cellular Fisiol & Immunol, Bellaterra 08193, Spain
ISSN: 14712407





BMC CANCER
Editorial
BMC, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 10 Número:
Páginas:
WOS Id: 000280355300001
ID de PubMed: 20540739
imagen Gold, Green Published

MÉTRICAS